Env-specific IgA from viremic HIV-infected subjects compromises antibodydependent cellular cytotoxicity

Journal of Virology

Volumn 90, Issue 2, 2016, Pages 670-681

  Ruiz, María Julia ^a   Ghiglione, Yanina ^a   Falivene, Juliana ^a   Laufer, Natalia ^a,c   Holgado, María Pía ^a   Socías, María Eugenia ^b,c   Cahn, Pedro ^b,c   Sued, Omar ^b,c   Giavedoni, Luis ^d   Salomón, Horacio ^a   Gherardi, María Magdalena ^a   Rodríguez, Ana María ^a   Turk, Gabriela ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b FUNDACIÓN HUÉSPED   (Argentina)

^c HOSPITAL JUAN A FERNÁNDEZ   (Argentina)

^d SOUTHWEST NATIONAL PRIMATE RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; GLYCOPROTEIN GP 120; GP120 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

ADULT; AGED; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY RESPONSE; ARTICLE; BLOOD SAMPLING; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; FLUOROMETRY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MIDDLE AGED; PRIORITY JOURNAL; YOUNG ADULT; IMMUNOLOGY; VIREMIA;

ADULT; AGED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; FLUOROMETRY; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HUMANS; IMMUNOGLOBULIN A; MALE; MIDDLE AGED; VIREMIA; YOUNG ADULT;

EID: 84954188252     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02363-15     Document Type: Article

References (38)

1. Maartens G, Celum C, Lewin SR. 2014. HIV infection: epidemiology, pathogenesis, treatment, and prevention. Lancet 384:258-271. http://dx.doi.org/10.1016/S0140-6736(14)60164-1.
2. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, Benenson M, Gurunathan S, Tartaglia J, McNeil JG, Francis DP, Stablein D, Birx DL, Chunsuttiwat S, Khamboonruang C, Thongcharoen P, Robb ML, Michael NL, Kunasol P, Kim JH. 2009. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361: 2209-2220. http://dx.doi.org/10.1056/NEJMoa0908492.
3. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, Liao HX, DeVico AL, Lewis GK, Williams C, Pinter A, Fong Y, Janes H, DeCamp A, Huang Y, Rao M, Billings E, Karasavvas N, Robb ML, Ngauy V, de Souza MS, Paris R, Ferrari G, Bailer RT, Soderberg KA, Andrews C, Berman PW, Frahm N, De Rosa SC, Alpert MD, Yates NL, Shen X, Koup RA, Pitisuttithum P, Kaewkungwal J, Nitayaphan S, Rerks-Ngarm S, Michael NL, Kim JH. 2012. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 366:1275-1286. http://dx.doi.org/10.1056/NEJMoa1113425.
4. Karnasuta C, Paris RM, Cox JH, Nitayaphan S, Pitisuttithum P, Thongcharoen P, Brown AE, Gurunathan S, Tartaglia J, Heyward WL, McNeil JG, Birx DL, de Souza MS. 2005. Antibody-dependent cellmediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand. Vaccine 23:2522-2529. http://dx.doi.org/10.1016/j.vaccine.2004.10.028.
5. Baum LL, Cassutt KJ, Knigge K, Khattri R, Margolick J, Rinaldo C, Kleeberger CA, Nishanian P, Henrard DR, Phair J. 1996. HIV-1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression. J Immunol 157:2168-2173.
6. Chung AW, Navis M, Isitman G, Centre R, Finlayson R, Bloch M, Gelgor L, Kelleher A, Kent SJ, Stratov I. 2011. Activation of NK cells by ADCC responses during early HIV infection. Viral Immunol 24:171-175. http://dx.doi.org/10.1089/vim.2010.0108.
7. Chung AW, Navis M, Isitman G, Wren L, Silvers J, Amin J, Kent SJ, Stratov I. 2011. Activation of NK cells by ADCC antibodies and HIV disease progression. J Acquir Immune Defic Syndr 58:127-131. http://dx.doi.org/10.1097/QAI.0b013e31822c62b9.
8. Forthal DN, Landucci G, Daar ES. 2001. Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells. J Virol 75:6953-6961. http://dx.doi.org/10.1128/JVI.75.15.6953-6961.2001.
9. Lambotte O, Ferrari G, Moog C, Yates NL, Liao HX, Parks RJ, Hicks CB, Owzar K, Tomaras GD, Montefiori DC, Haynes BF, Delfraissy JF. 2009. Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS 23:897-906. http://dx.doi.org/10.1097/QAD.0b013e328329f97d.
10. Stratov I, Chung A, Kent SJ. 2008. Robust NK cell-mediated human immunodeficiency virus (HIV)-specific antibody-dependent responses in HIV-infected subjects. J Virol 82:5450-5459. http://dx.doi.org/10.1128/JVI.01952-07.
11. Thobakgale CF, Fadda L, Lane K, Toth I, Pereyra F, Bazner S, Ndung'u T, Walker BD, Rosenberg ES, Alter G, Carrington M, Allen TM, Altfeld M. 2012. Frequent and strong antibody-mediated natural killer cell activation in response to HIV-1 Env in individuals with chronic HIV-1 infection. J Virol 86:6986-6993. http://dx.doi.org/10.1128/JVI.00569-12.
12. Nag P, Kim J, Sapiega V, Landay AL, Bremer JW, Mestecky J, Reichelderfer P, Kovacs A, Cohn J, Weiser B, Baum LL. 2004. Women with cervicovaginal antibody-dependent cell-mediated cytotoxicity have lower genital HIV-1 RNA loads. J Infect Dis 190:1970-1978. http://dx.doi.org/10.1086/425582.
13. Battle-Miller K, Eby CA, Landay AL, Cohen MH, Sha BE, Baum LL. 2002. Antibody-dependent cell-mediated cytotoxicity in cervical lavage fluids of human immunodeficiency virus type 1-infected women. J Infect Dis 185:439-447. http://dx.doi.org/10.1086/338828.
14. Mabuka J, Nduati R, Odem-Davis K, Peterson D, Overbaugh J. 2012. HIV-specific antibodies capable of ADCC are common in breastmilk and are associated with reduced risk of transmission in women with high viral loads. PLoS Pathog 8:e1002739. http://dx.doi.org/10.1371/journal.ppat.1002739.
15. Wren LH, Chung AW, Isitman G, Kelleher AD, Parsons MS, Amin J, Cooper DA, Stratov I, Navis M, Kent SJ. 2013. Specific antibodydependent cellular cytotoxicity responses associated with slow progression of HIV infection. Immunology 138:116-123. http://dx.doi.org/10.1111/imm.12016.
16. Tiemessen CT, Shalekoff S, Meddows-Taylor S, Schramm DB, Papathanasopoulos M, Gray G, Sherman G, Coovadia A, Kuhn L. 2010. Natural killer cells that respond to human immunodeficiency virus type 1 (HIV-1) peptides are associated with control of HIV-1 infection. J Infect Dis 202: 1444-1453. http://dx.doi.org/10.1086/656535.
17. Johansson SE, Rollman E, Chung AW, Center RJ, Hejdeman B, Stratov I, Hinkula J, Wahren B, Karre K, Kent SJ, Berg L. 2011. NK cell function and antibodies mediating ADCC in HIV-1-infected viremic and controller patients. Viral Immunol 24:359-368. http://dx.doi.org/10.1089/vim.2011.0025.
18. Chung AW, Rollman E, Center RJ, Kent SJ, Stratov I. 2009. Rapid degranulation ofNKcells following activation by HIV-specific antibodies. J Immunol 182:1202-1210. http://dx.doi.org/10.4049/jimmunol.182.2.1202.
19. Dugast AS, Stamatatos L, Tonelli A, Suscovich TJ, Licht AF, Mikell I, Ackerman ME, Streeck H, Klasse PJ, Moore JP, Alter G. 2014. Independent evolution of Fc-and Fab-mediated HIV-1-specific antiviral antibody activity following acute infection. Eur J Immunol 44:2925-2937. http://dx.doi.org/10.1002/eji.201344305.
20. + T cells is directly associated with the magnitude of surface IgG binding. J Virol 86:8672-8680. http://dx.doi.org/10.1128/JVI.00287-12.
21. Milligan C, Richardson BA, John-Stewart G, Nduati R, Overbaugh J. 2015. Passively acquired antibody-dependent cellular cytotoxicity (ADCC) activity in HIV-infected infants is associated with reduced mortality. Cell Host Microbe 17:500-506. http://dx.doi.org/10.1016/j.chom.2015.03.002.
22. Ljunggren K, Broliden PA, Morfeldt-Manson L, Jondal M, Wahren B. 1988. IgG subclass response toHIVin relation to antibody-dependent cellular cytotoxicity at different clinical stages. Clin Exp Immunol 73:343-347.
23. Tomaras GD, Ferrari G, Shen X, Alam SM, Liao HX, Pollara J, Bonsignori M, Moody MA, Fong Y, Chen X, Poling B, Nicholson CO, Zhang R, Lu X, Parks R, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Rerks-Ngarm S, Gilbert PB, Kim JH, Michael NL, Montefiori DC, Haynes BF. 2013. Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Proc Natl Acad Sci U S A 110:9019-9024. http://dx.doi.org/10.1073/pnas.1301456110.
24. Mota G, Manciulea M, Cosma E, Popescu I, Hirt M, Jensen-Jarolim E, Calugaru A, Galatiuc C, Regalia T, Tamandl D, Spittler A, Boltz-Nitulescu G. 2003. Human NK cells express Fc receptors for IgA which mediate signal transduction and target cell killing. Eur J Immunol 33: 2197-2205. http://dx.doi.org/10.1002/eji.200323534.
25. Socias ME, Sued O, Laufer N, Lazaro ME, Mingrone H, Pryluka D, Remondegui C, Figueroa MI, Cesar C, Gun A, Turk G, Bouzas MB, Kavasery R, Krolewiecki A, Perez H, Salomon H, Cahn P. 2011. Acute retroviral syndrome and high baseline viral load are predictors of rapid HIV progression among untreated Argentinean seroconverters. J Int AIDS Soc 14:40. http://dx.doi.org/10.1186/1758-2652-14-40.
26. + T-cell memory phenotypes during primary HIV infection is related to reduced antiviral activity and faster disease progression. PLoS One 9:e104235. http://dx.doi.org/10.1371/journal.pone.0104235.
27. + T-cell compartment. J Virol 87:7445-7462. http://dx.doi.org/10.1128/JVI.00865-13.
28. Giavedoni LD. 2005. Simultaneous detection of multiple cytokines and chemokines from nonhuman primates using Luminex technology. J Immunol Methods 301:89-101. http://dx.doi.org/10.1016/j.jim.2005.03.015.
29. Gomez-Roman VR, Florese RH, Patterson LJ, Peng B, Venzon D, Aldrich K, Robert-Guroff M. 2006. A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity. J Immunol Methods 308:53-67. http://dx.doi.org/10.1016/j.jim.2005.09.018.
30. Howell DN, Andreotti PE, Dawson JR, Cresswell P. 1985. Natural killing target antigens as inducers of interferon: studies with an immunoselected, natural killing-resistant human T lymphoblastoid cell line. J Immunol 134:971-976.
31. Fiebig EW, Wright DJ, Rawal BD, Garrett PE, Schumacher RT, Peddada L, Heldebrant C, Smith R, Conrad A, Kleinman SH, Busch MP. 2003. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 17:1871-1879. http://dx.doi.org/10.1097/00002030-200309050-00005.
32. Madhavi V, Wren LH, Center RJ, Gonelli C, Winnall WR, Parsons MS, Kramski M, Kent SJ, Stratov I. 2014. Breadth of HIV-1 Env-specific antibody-dependent cellular cytotoxicity: relevance to global HIV vaccine design. AIDS 28:1859-1870. http://dx.doi.org/10.1097/QAD.0000000000000310.
33. Richard J, Veillette M, Batraville LA, Coutu M, Chapleau JP, Bonsignori M, Bernard N, Tremblay C, Roger M, Kaufmann DE, Finzi A. 2014. Flow cytometry-based assay to study HIV-1 gp120 specific antibody-dependent cellular cytotoxicity responses. J Virol Methods 208:107-114. http://dx.doi.org/10.1016/j.jviromet.2014.08.003.
34. Veillette M, Desormeaux A, Medjahed H, Gharsallah NE, Coutu M, Baalwa J, Guan Y, Lewis G, Ferrari G, Hahn BH, Haynes BF, Robinson JE, Kaufmann DE, Bonsignori M, Sodroski J, Finzi A. 2014. Interaction with cellular CD4 exposes HIV-1 envelope epitopes targeted by antibodydependent cell-mediated cytotoxicity. J Virol 88:2633-2644. http://dx.doi.org/10.1128/JVI.03230-13.
35. Veillette M, Coutu M, Richard J, Batraville LA, Dagher O, Bernard N, Tremblay C, Kaufmann DE, Roger M, Finzi A. 2015. The HIV-1 gp120 CD4-bound conformation is preferentially targeted by antibodydependent cellular cytotoxicity-mediating antibodies in sera from HIV-1-infected individuals. J Virol 89:545-551. http://dx.doi.org/10.1128/JVI.02868-14.
36. Ferrari G, Pollara J, Kozink D, Harms T, Drinker M, Freel S, Moody MA, Alam SM, Tomaras GD, Ochsenbauer C, Kappes JC, Shaw GM, Hoxie JA, Robinson JE, Haynes BF. 2011. An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum. J Virol 85:7029-7036. http://dx.doi.org/10.1128/JVI.00171-11.
37. Richard J, Veillette M, Brassard N, Iyer SS, Roger M, Martin L, Pazgier M, Schon A, Freire E, Routy JP, Smith AB, III, Park J, Jones DM, Courter JR, Melillo BN, Kaufmann DE, Hahn BH, Permar SR, Haynes BF, Madani N, Sodroski JG, Finzi A. 2015. CD4 mimetics sensitize HIV-1-infected cells to ADCC. Proc Natl Acad Sci U S A 112:E2687-E2694. http://dx.doi.org/10.1073/pnas.1506755112.
38. Zhou M, Ruprecht RM. 2014. Are anti-HIV IgAs good guys or bad guys? Retrovirology 11:109. http://dx.doi.org/10.1186/s12977-014-0109-5.